Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 6/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22897402 | 0.91 | ALDH1A1 (0.36) | ALDH1A1KDM4E | |
| SCHEMBL22906079 | 0.88 | ALDH1A1 (0.33) | ALDH1A1MAPTL3MBTL1LMNAKDM4E | |
| SCHEMBL22897394 | 0.88 | ALDH1A1 (0.33) | ALDH1A1MAPTL3MBTL1LMNAKDM4E | |
| SCHEMBL22897420 | 0.82 | TDP1 (0.34) | ALDH1A1MAPTL3MBTL1LMNAKDM4E | |
| SCHEMBL26225285 | 0.80 | MAPT (0.36) | ALDH1A1MAPTL3MBTL1LMNAKDM4E | |
| SCHEMBL26225284 | 0.80 | MAPT (0.36) | ALDH1A1MAPTL3MBTL1LMNAKDM4E | |
| SCHEMBL22897398 | 0.80 | ALDH1A1 (0.35) | ALDH1A1KDM4E | |
| SCHEMBL8412359 | 0.79 | MAPT (0.32) | ALDH1A1MAPTL3MBTL1LMNAKDM4E | |
| SCHEMBL22897396 | 0.78 | L3MBTL1 (0.37) | ALDH1A1MAPTL3MBTL1LMNAKDM4E | |
| SCHEMBL23268467 | 0.77 | TDP1 (0.36) | ALDH1A1MAPTL3MBTL1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744916-B2 | Radiopaque polymers | BIOCOMPATIBLES UK LIMITED | 2023-09-05 | — | — | US | disclosed |
| US-11702498-B2 | Radiopaque polymers | BIOCOMPATIBLES UK LIMITED | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702498-B2 | Radiopaque polymers | OXER1, NR5A1, AQP1 | ALDH1A1 3178/4885MAPT 4575/4885L3MBTL1 3906/4885 |
| US-11744916-B2 | Radiopaque polymers | TPO, PGLS, IQGAP1 | ALDH1A1 1464/4885MAPT 4511/4885L3MBTL1 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.